Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 250 c. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf. Последний доступ 08.10.2019.http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 250 c. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf. Последний доступ 08.10.2019.http://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf
Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. Режим доступа: http://www.oncology.ru/service/statistics/condition/2018.pdf. Последний доступ: 05.10.2019.http://www.oncology.ru/service/statistics/condition/2018.pdf
Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. Режим доступа: http://www.oncology.ru/service/statistics/condition/2018.pdf. Последний доступ: 05.10.2019.http://www.oncology.ru/service/statistics/condition/2018.pdf
Stratton J.F., Pharoah P., Smith S.K., Easton D., Ponder B.A.J. A systematic review and metaanalysis of family history and risk of ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology. 1998;105(5):493-499. doi: 10.1111/j.1471-0528.1998.tb10148.x..
DOI: 10.1111/j.1471-0528.1998.tb10148.x
Tyulyandina A., Gorbunova V., Khokhlova S., et al. Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study. AACR Annual Meeting. 2018; April 14-18, 2018. doi: 10.1158/1538-7445.AM2018-1241..
DOI: 10.1158/1538-7445.AM2018-1241
Soegaard M., Kjaer S.K., Cox M., et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research. 2008;14(12):3761-3767. doi: 10.1158/1078-0432.CCR-07-4806..
DOI: 10.1158/1078-0432.CCR-07-4806
George A., Kaye S., Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature Reviews Clinical Oncology. 2017;14(5):284-296. doi: 10.1038/nrclinonc.2016.191..
DOI: 10.1038/nrclinonc.2016.191
Møller P., Hagen A.I., Apold J., et al. Genetic epidemiology of BRCA mutations – family history detects less than 50[%] of the mutation carriers. European Journal of Cancer. 2007;43(11):1713-1717. doi: 10.1016/j.ejca.2007.04.023.
DOI: 10.1016/j.ejca.2007.04.023
Alsop K., Fereday S., Meldrum C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology. 2012;30(21):2654-2663. doi: 10.1200/JCO.2011.39.8545..
DOI: 10.1200/JCO.2011.39.8545
Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian Cancer Risk in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations. Clin Cancer Res. 2002;8(12):3776-3781.
Yun M.H., Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochemical Society Transactions. 2009;37(3):597-604. doi: 10.1042/BST0370597..
DOI: 10.1042/BST0370597
Ashworth A. A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair. Journal of Clinical Oncology. 2008;26(22):3785-3790. doi: 10.1200/JCO.2008.16.0812..
DOI: 10.1200/JCO.2008.16.0812
Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D’Andrea A.D. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discovery. 2015;5(11):1137-1154. doi: 10.1158/2159-8290.CD-15-0714..
DOI: 10.1158/2159-8290.CD-15-0714
Mirza M.R., Monk B.J., Herrstedt J., et al. Niraparib Maintenance Therapy in PlatinumSensitive, Recurrent Ovarian Cancer. New England Journal of Medicine. 2016;375(22):2154-2164. doi: 10.1056/NEJMoa1611310..
DOI: 10.1056/NEJMoa1611310
Coleman R.L., Oza A.M., Lorusso D., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6..
DOI: 10.1016/S0140-6736(17)32440-6
Pujade-Lauraine E., Ledermann J.A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-сontrolled, phase 3 trial. The Lancet Oncology. 2017;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2..
DOI: 10.1016/S1470-2045(17)30469-2
Ledermann J., Harter P., Gourley C., et al. Olaparib Maintenance Therapy in PlatinumSensitive Relapsed Ovarian Cancer. New England Journal of Medicine. 2012;366(15):1382-1392. doi:10.1056/NEJMoa1105535..
DOI: 10.1056/NEJMoa1105535
McNeish I.A., Ledermann J.A., Webber L., et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Annals of Oncology. 2014;25(10):1988-1995. doi: 10.1093/annonc/mdu363..
DOI: 10.1093/annonc/mdu363
Ledermann J.A., Harter P., Gourley C., et al. Overall survival in patients with platinumsensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Oncology. 2016;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X..
DOI: 10.1016/S1470-2045(16)30376-X
Friedlander M., Matulonis U., Gourley C., et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer. 2018;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y..
DOI: 10.1038/s41416-018-0271-y
Ledermann J., Harter P, Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15(8):852-861. doi: 10.1016/S1470-2045(14)70228-1..
DOI: 10.1016/S1470-2045(14)70228-1
Любченко Л.Н., Батенева Е.И., Абрамов И.С. и соавт. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013;(2):53-61. doi: 10.18027/2224-5057-2013-2-53-61..
DOI: 10.18027/2224-5057-2013-2-53-61
Plon S.E., Eccles D.M., Easton D., et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation. 2008;29(11):1282-1291. doi: 10.1002/humu.20880..
DOI: 10.1002/humu.20880
Kolor K., Chen Z., Grosse S.D., et al. BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas – United States, 2009–2014. MMWR Surveillance Summaries. 2017;66(15):1-11. doi: 10.15585/mmwr.ss6615a1..
DOI: 10.15585/mmwr.ss6615a1
Cline M.S., Babbi G., Bonache S., et al. Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants. Human Mutation. 2019;40(9):1546-1556. doi: 10.1002/humu.23861..
DOI: 10.1002/humu.23861
Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals. Journal of Clinical Oncology. 2002;20(6):1480-1490. doi: 10.1200/JCO.2002.20.6.1480..
DOI: 10.1200/JCO.2002.20.6.1480
Gunderson C.C., Matulonis U., Moore K.N. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecologic Oncology. 2018;148(3):591-600. doi: 10.1016/j.ygyno.2018.01.010..
DOI: 10.1016/j.ygyno.2018.01.010
Friedlander M., Gebski V., Gibbs E., et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinumsensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. The Lancet Oncology. 2018;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7..
DOI: 10.1016/S1470-2045(18)30343-7
Robson M.E., Tung N., Conte P., et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology. 2019;30(4):558-566. doi: 10.1093/annonc/mdz012.
DOI: 10.1093/annonc/mdz012